Skip to main content

Table 3 Average 2-[18F]FDG SUV metrics (± 1 STD) for KRAS wild-type and missense mutated CLM obtained with two independent volume segmentations (MIM and HERMES)

From: KRAS mutation effects on the 2-[18F]FDG PET uptake of colorectal adenocarcinoma metastases in the liver

 

Mean uptake

Peak uptake

Max uptake

 

KRAS wild-type

KRAS+

KRAS wild-type

KRAS+

KRAS wild-type

KRAS+

SUV (MIM)

5.70 ± 1.82

6.91 ± 2.46

6.56 ± 2.61

8.29 ± 4.04

8.63 ± 3.74

11.79 ± 5.17

SUV (HERMES)

5.63 ± 1.46

6.65 ± 1.68

7.09 ± 2.97

9.21 ± 4.33

8.63 ± 3.74

11.79 ± 5.17

SUV MIM + PVEC

7.13 ± 2.62

8.94 ± 3.26

7.63 ± 2.92

9.79 ± 3.93

9.44 ± 3.89

13.09 ± 4.96

SUV (HERMES) + PVEC

7.00 ± 2.12

8.37 ± 1.86

8.18 ± 3.17

10.53 ± 3.95

9.33 ± 3.66

12.63 ± 4.68

SUV (MIM) + PVEC + Time corr

5.98 ± 2.39

7.74 ± 3.18

6.42 ± 2.74

8.44 ± 3.66

7.92 ± 3.57

11.19 ± 4.46

SUV (HERMES) + PVEC + Time corr

5.87 ± 2.14

7.22 ± 1.92

6.88 ± 3.04

8.99 ± 3.44

7.83 ± 3.45

10.77 ± 4.05

SUVTLR (MIM) + PVEC

2.64 ± 1.11

3.54 ± 1.53

2.81 ± 1.20

3.92 ± 1.91

3.51 ± 1.66

5.28 ± 2.61

SUVTLR (HERMES) + PVEC

2.62 ± 1.08

3.35 ± 1.16

3.06 ± 1.43

4.27 ± 2.16

3.49 ± 1.63

5.12 ± 2.56

SUR (MIM) Time corr

2.10 ± 0.89

2.77 ± 0.83

2.43 ± 1.24

3.30 ± 1.43

3.20 ± 1.74

4.66 ± 1.81

SUR (HERMES) Time corr

2.06 ± 0.81

2.70 ± 0.67

2.63 ± 1.40

3.65 ± 1.53

3.20 ± 1.74

4.66 ± 1.81

SUR (MIM) + PVEC + Time corr

2.60 ± 1.17

3.59 ± 1.15

2.80 ± 1.35

3.93 ± 1.43

3.47 ± 1.79

5.23 ± 1.79

SUR (HERMES) + PVEC + Time corr

2.55 ± 1.07

3.42 ± 0.85

3.01 ± 1.52

4.23 ± 1.46

3.43 ± 1.75

5.06 ± 1.72

  1. KRAS gene amplification cases (n = 3) are grouped with wild type. Average metrics values after PVE and uptake time correction are provided for the derivative metrics tumor-to-liver ratio (SUVTLR) and tumor-to-blood ratio (SUR) as well